Search results: (10000)
News Continuation of Treatment with Tofacitinib in Rheumatoid Arthritis – Real-World Clinical Practice Data
The oral Janus kinase inhibitor tofacitinib has been extensively tested in patients with rheumatoid arthritis in numerous international randomized clinical trials. According to a recently published review summarizing retrospective, prospective, and observational studies from real-world clinical practice published in 2018–2020, the treatment duration with tofacitinib is comparable to that with biological disease-modifying drugs.
News Long-term Clinical and Radiological Results of Implantation of Cementless Corail Stem
The Corail femoral stem with extensive hydroxyapatite coating for cementless implantation was introduced to the market several decades ago. The study cited below evaluated the clinical and radiological results of the implantation of this type of stem over a 20-year horizon in patients who underwent primary total hip arthroplasty.
News Antiviral and Anti-inflammatory Effects of Alpha-1-Antitrypsin in the Treatment of COVID-19
Human alpha-1-antitrypsin (AAT) is a circulating blood glycoprotein that has been used for decades in the treatment of patients with AAT deficiency, lung damage, and emphysema, helping to prevent acute lung injury. Recently, it has been found that AAT also mitigates the course of COVID-19 disease by hindering the entry of the SARS-CoV-2 coronavirus into host cells. This dual antiviral and anti-inflammatory action makes AAT an excellent candidate for COVID-19 treatment.
News Effect of Trifluridine/Tipiracil Combination Depending on Patient Prognosis
The results of the RECOURSE clinical study were published in 2015 and became an important basis for the approval of the trifluridine/tipiracil combination in the treatment of metastatic colorectal cancer (mCRC). The data obtained in this study were also subjected to several post-hoc analyses. One of these recently brought information on how patient prognosis affects the clinical outcomes of this treatment.
News Less Ventricular Arrhythmias and ICD Shocks After Introduction of Sacubitril/Valsartan
Is the decrease in the incidence of sudden cardiac death among patients using sacubitril/valsartan due to a lower risk of ventricular arrhythmias? And does it have anything to do with reverse left ventricular remodeling? A newly published study utilizing data from telemonitoring of patients with implanted devices focused on this.
News How Common is Alpha-1 Antitrypsin Deficiency?
What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are associated with it? Are healthcare costs for these patients higher compared to patients with unrelated obstructive lung diseases? Awareness of AATD is low and prevalence data are only indicative. The authors of a study published in the European Respiratory Journal aimed to map this disease in a population of 4 million German insured individuals.
News Impact of Alpha-1 Antitrypsin Deficiency on Quality of Life and Mental Health of Patients
The clinical manifestation of alpha-1 antitrypsin deficiency and its impact on quality of life are highly heterogeneous. This contribution by pulmonologist Robert Sandhaus summarizes interesting findings from studies on the quality of life of patients with this disease and the factors influencing it.
News Deep stimulation of the globus pallidus improved clinical symptoms in a patient with refractory parkinsonism and genetic mutation
The authors of the presented work studied the effects of deep brain stimulation (DBS) in a patient with Parkinson's disease with a genetic mutation that manifests in early adulthood.
News Ceftaroline vs. Vancomycin in the Treatment of Acute Pulmonary Exacerbation of Cystic Fibrosis
Up to 25% of patients with cystic fibrosis are colonized with methicillin-resistant Staphylococcus aureus (MRSA). The first-line drug for acute pulmonary exacerbation is vancomycin. The study presented below examined the efficacy and safety of an alternative treatment with ceftaroline (a 5th generation cephalosporin) for this indication.
News Overlap of SGLT2 Inhibitors from Diabetology to Cardiology
As recent research shows, one of the modern groups of antidiabetic drugs - SGLT2 inhibitors, also known as gliflozins - brings benefits not only in diabetology but also in cardiology and nephrology. It has been confirmed that representatives of this class of drugs prolong patients' lives, reduce the incidence of major cardiovascular (CV) events and the risk of heart failure (HF), and improve renal function. A recently published study additionally indicates that the CV benefit of empagliflozin is independent of the number of compensated CV risk factors and manifests within the first 3 months of treatment.
News Effect of Cataract Surgery on Melatonin Secretion in Adults Aged 60 and Over
A study by ophthalmologists and epidemiologists from Nara University in Japan, recently published in JAMA Ophthalmology, examined the relationship between cataract surgery, the use of clear and yellow intraocular lenses, and the level of melatonin secretion.
News Alleviation of Asthma and Chronic Sinusitis Symptoms in Patients with Atopic Dermatitis Thanks to Dupilumab
An analysis of results in adult patients with moderate to severe atopic dermatitis, who also had asthma and/or chronic rhinosinusitis, investigated how clinically and statistically significant the benefit of dupilumab is for all these 3 conditions in comparison with a placebo.
News Subcutaneous Immunoglobulin Therapy in Patients with Secondary Immunodeficiency – Real-World Data
Even in patients with secondary immunodeficiency (SID), immunoglobulin substitution can be indicated. Intravenous (IVIG) therapy is considered effective based on studies, but subcutaneous (SCIG) therapy is only based on experiences with patients having primary immunodeficiency (PID). The Italian study presented below, therefore, investigated the efficacy and safety of SCIG in patients with SID.
News Effectiveness and Safety of Initiating Treatment for Primary Immunodeficiency with Subcutaneously Administered Immunoglobulins – A Systematic Review of the Literature
The aim of the systematic review of the literature published last year was to evaluate the effectiveness and safety of initiating treatment with subcutaneously administered immunoglobulins (SCIG) in patients with primary immunodeficiency (PID) who had not previously been treated with this modality. There was insufficient data available for such a defined population because SCIGs had typically been introduced into studies only after intravenously administered immunoglobulins (IVIG).
News Nirmatrelvir/ritonavir reduces the risk of hospitalization for COVID-19 even in the era of predominant omicron subvariants BA.4 and BA.5
One of the first studies to evaluate the efficacy of nirmatrelvir/ritonavir in non-hospitalized patients with COVID-19 infection during the period of predominant omicron variants including subvariants BA.4 and BA.5 has provided real-world data confirming the position of this antiviral in the first line of treatment for patients with mild to moderately severe SARS-CoV-2 infection and a high risk of severe disease.
News Laboratory Safety of Dupilumab Treatment in Children with Atopic Dermatitis Aged 6 Months to 6 Years
Previous clinical studies in children aged 6–12 years with moderate-to-severe atopic dermatitis have demonstrated laboratory safety during dupilumab treatment. The randomized study presented below supplements the data for the age group from 6 months to 6 years.
News The World of Viruses is Constantly Evolving and Bringing Us New Surprises
The last decade has been marked by the emergence of new, as well as re-emerging human pathogens responsible for various infectious diseases. Viruses, especially those of zoonotic origin that originate in the wild, are demanding significant attention—and rightly so. This group of viruses currently accounts for 70% of infectious diseases in the human population, with many using animal organisms as vectors (e.g., ticks, mosquitoes) to transport and infect the human body. Human-vector interactions are becoming increasingly common, particularly due to ongoing urbanization, encroachment into previously uninhabited areas, population migration, increasing travel, shrinking distances, and climate change. In the following text, we will look at some specific examples.
News Do real-world clinical practice data confirm the results of cenobamate treatment in the clinical program?
A recent study by Spanish authors presents the largest dataset of patients with published cenobamate treatment results under prolonged observation in real-world clinical practice at the time of article publication. Data are derived from an expanded access program for a population with highly drug-resistant focal seizures.
News Safety of aPCC in Real Practice – Results of the BAHAS Project
What are the experiences with activated prothrombin complex concentrate (aPCC) in controlling bleeding or preventing its recurrence in acquired hemophilia A? The BAHAS project from Spanish real practice offers answers.
News Thromboprophylaxis in Generalized Pancreatic Cancer
Pancreatic adenocarcinoma is one of the tumors with the highest risk of developing thromboembolic disease (TED). Although anticoagulant treatment reduces the risk of TED, its positive effect on the overall survival of patients has not yet been proven.
News Does Emicizumab Change Routine Clinical Practice?
With the increasing number of patients with hemophilia A being treated with emicizumab, the question arises whether its use in any way changes established clinical practice. A team of American authors sought answers based on a survey conducted among the treating physicians of these patients. The findings were presented at the 13th Annual EAHAD Congress, which took place at the beginning of February in The Hague, Netherlands.
News Monocyte Distribution Width as an Early Indicator of Sepsis in ICU Patients
Authors of a Franco-Spanish study propose using the monocyte distribution width along with leukocyte count as a screening test to refine the early diagnosis of sepsis in intensive care unit (ICU) patients based on their research findings.
News What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?
Fresh findings from the BE ACTIVE study were published this year in the journal Rheumatology, which evaluated the effects of long-term treatment of individuals with psoriatic arthritis (PsA) with bimekizumab in terms of patient-reported outcomes (PROs).
News Facilitated Immunoglobulin Substitution Therapy in Paediatric Patients with Immunodeficiency – Real-World Data
Patients with humoral immunodeficiency are indicated for immunoglobulin substitution therapy. The study presented below summarizes real-world data concerning the latest substitution method (i.e., facilitated subcutaneous administration) in paediatric patients.